“…SLITRK5 was generally expressed in the developing central nervous system at times and locations that are important to neuronal morphogenesis and synaptogenesis (Beaubien & Cloutier, 2009;Round et al, 2014), as well as in embryonic stem cells, subsets of endothelial cells, hematopoietic stem cells, and in leukemia and lymphoma cells . SLITRK5 is associated with many neurological disorders (Liu et al, 2022), which can be combined with the synaptic adhesion molecules (SAMs), type IIa receptor protein tyrosine phosphatase (RPTP), controlling synapse formation, thus regulating the connections between neurons (Beaubien et al, 2016;O'Sullivan et al, 2012;Shmelkov et al, 2001;Song et al, 2015).Additionally, SLITRK5 is associated with a variety of tumors, such as brain glioma, thyroid tumors, gastric cancer, nasopharyngeal carcinoma, lung squamous cell carcinoma, and colorectal tumor (Haoran & Yanhua, 2018;Heiliger et al, 2012;Hesson et al, 2016;Ju et al, 2020;Li et al, 2016;Park et al, 2016). Beyond that, SLITRK5 can negatively regulate dendritic growth, controlling the inhibitory synapse formation on dopamine neurons and modulating hyperactivity behavior (Salesse et al, 2020).…”